On behalf of HNCA’s board and staff, we would like to wish our friends and supporters a Happy Thanksgiving. This Thanksgiving, we are thankful for the courage of patients and survivors, the dedication of caregivers, the commitment and expertise of health care professionals, and the many people who are helping to make a difference by encouraging efforts towards prevention and finding a cure. We keep in our hearts those that have lost their battles with head and neck cancer, but whose loved ones continue to find inspiration in their memory and in making a difference.
The Head & Neck Cancer Alliance Team
Rob Paulsen Chosen as HNCA's 2020 OHANCA® Spokesperson
HNCA has selected voice actor and throat cancer survivor, Rob Paulsen, as its official spokesperson for 2020. Paulsen will serve as the face and voice of HNCA’s Oral, Head and Neck Cancer Awareness® Program (OHANCA®), which celebrates its 22nd year in 2020.
*Sponsor content.Learn HNCA’s stance on corporate support below.
Clinical trials are research studies that involve patients. Through clinical trials, doctors and researchers find new ways to improve treatments and the quality of life for people with diseases. For more information about clinical trials and where to find trials that might apply to you or a loved one, visit our Clinical Trials page.
Clinical Trial Opportunity for Head & Neck Cancer with FGFR 1, 2, or 3 Fusions
The FUZE Clinical Trial is evaluating an oral investigational medication, called Debio 1347, that may block cancer cell growth. You may qualify if you have an advanced head or neck cancer with a specific genetic alteration, called a fusion of FGFR 1, 2, or 3 receptor. If your head or neck cancer has progressed after treatment, ask your doctor about a new clinical trial that focuses on this specific genetic alteration. Every tumor has a genetic makeup. Learn more at FuzeTrial.com.
Clinical Trial Opportunity for Head & Neck Cancer with HRAS Mutations
Tipifarnib is an investigational drug that is currently being studied for the treatment of Head and Neck cancer. It prevents protein farnesylation, a key cell signaling process implicated in cancer initiation and development.
The tipifarnib clinical trial is open to male and female patients 18 years of age or older with Squamous Cell Head and Neck Cancer that carry HRAS mutations. Testing of tumors for HRAS mutations is provided at no cost to patients. Learn more.
Clinical Trial Opportunity for Recurrent and/or Metastatic Head & Neck Cancer
Patients are now being enrolled in a Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) for the Treatment of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Learn more.
*Statement on Sponsor Content and Corporate Support: The information published on this website and in our materials is intended to educate you about Oral, Head and Neck Cancer. The content is not intended to take the place of a discussion with a qualified physician who is familiar with your medical situation. It is important to remember that each individual is different, and the reasons for—and outcomes of—any treatment plan depends on the patient's individual condition. If you have questions or concerns after reading any information on this website or in our materials, you should discuss them openly and honestly with your physician. Any products and manufacturers included on this site are presented for informational purposes only and do not constitute product approval or endorsement by HNCA. The content provided by HNCA is in no way intended to be a substitute for medical consultation with a qualified professional. HNCA encourages those using its resources to be careful when evaluating medical information or products. If you are unsure about your medical condition, consult a physician. Funding from our corporate partners supports HNCA’s programs and educational initiatives, and HNCA maintains independence in its design of programs, content, and initiatives.
THANK YOU TO OUR CORPORATE AND COMMUNITY PARTNERS!